ESMO 2023 | Updates in ICIs and ADCs in cervical cancer

Benoit You, MD, PhD, Lyon University Hospital, Lyon, France, gives an overview of clinical trials assessing immunotherapies in cervical cancer. Findings from the Phase III KEYNOTE-A18 trial (NCT04221945) of chemoradiotherapy with or without pembrolizumab, an immune checkpoint inhibitor (ICI), demonstrated superior progression-free survival in patients who received pembrolizumab. The Phase III innovaTV 301 trial (NCT04697628) additionally highlighted the benefits of tisotumab vedotin, a novel antibody-drug conjugate (ADC). This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.